Relapse of aplastic anemia with majority donor chimerism (donor-type aplasia) occurring late after bone marrow transplantation

The treatment of choice for paediatric severe aplastic anaemia (SAA) is currently a human leucocyte antigen (HLA) matched sibling donor (MSD) transplant, with 2-5 year overall survival of 82-92% [1 –4]. Historically, immunosuppressive therapy (IST) was given to those who lacked a MSD but matched unrelated donor (MUD) transplant is now considered an alternative upfront treatment if a donor can be found quickly [2]. This change partly reflects excellent results from alternative donor transplan ts but also lack of consistent long-term remission for those treated with IST alone [5–7].

Source: Biology of Blood and Marrow Transplantation - November 12, 2019 Category: Hematology Authors: Abigail Shaw, Jakob R. Passweg, Josu De La Fuente, Rajinder Bajwa, Jerry Stein, Abdulhadi Al-Zaben, Constantijn J.M. Halkes, Alice Norton, Michelle Cummins, John P. Moppett, Mayada Abu Shanap, Colin G. Steward Source Type: research